When a clinical laboratory receives a new lot of reagent for a test it is already running, it cannot simply put that lot into service on the assumption that it performs identically to the lot it replaces. Reagent manufacturing varies lot to lot — in raw material, antibody titer, calibration alignment, and manufacturing conditions — enough that CLIA and CAP both expect the laboratory to demonstrate, with its own data, that a new lot produces results consistent with the lot it is replacing before reporting patient results from it. That demonstration is reagent lot-to-lot verification.
What is a reagent lot, and why does lot-to-lot verification exist
A reagent lot is a defined batch of reagent manufactured together under the same conditions and assigned a single lot number (sometimes called a batch number) by the manufacturer. Everything in that lot — every vial, bottle, or cartridge carrying that lot number — is presumed to share the same performance characteristics, because it came from the same manufacturing run, the same raw material inputs, and the same in-process quality control. A new lot number means a new manufacturing run, and manufacturing runs are not guaranteed to be identical even when the reagent formulation itself hasn’t changed on paper.
For a laboratory, that lot number is the traceability anchor: it links a specific result back to the specific reagent batch used to generate it, which is why lot numbers are recorded in QC logs, instrument audit trails, and (for many analytes) the patient result record itself. Verifying a new lot before use, and documenting that verification against the specific lot number, is what keeps that traceability chain meaningful rather than a formality.
The regulatory basis: CLIA and CAP
Under CLIA (42 CFR Part 493, Subpart K — Quality System for Nonwaived Testing), laboratories performing moderate- or high-complexity testing are required to have control procedures that monitor the accuracy and precision of the complete analytic process, and to verify performance specifications any time a change occurs that could affect test performance — a new reagent lot is treated as exactly that kind of change for most nonwaived assays.
CAP’s accreditation checklists operationalize this requirement into a specific, auditable expectation: laboratories must have a documented procedure for verifying new reagent lots (and new shipments of existing lots, where performance drift is a realistic risk) before the new lot is placed into clinical use, and must retain records showing the verification was actually performed and reviewed. This requirement is commonly cited by inspectors under the CAP checklist item number COM.30450 in current General/Common checklist editions covering new lot and new shipment verification — CAP renumbers and revises checklist items between accreditation cycles, so confirm the exact current item number and wording against your laboratory’s active CAP checklist edition rather than relying on any single cited number, including this one, as permanently fixed.
Waived testing sites are not held to the same nonwaived-testing control-procedure regulations, but CLIA still requires waived tests to be performed according to the manufacturer’s instructions — and many manufacturer package inserts for waived assays independently instruct the operator to run controls with each new reagent lot or shipment before reporting patient results, which has the practical effect of requiring a lightweight version of lot verification even at CLIA-waived sites.
New reagent lot verification procedure
The core method is comparative: run the new lot and the current (in-use) lot side by side on the same specimens or control materials, under the same conditions, and confirm the two lots agree within a predefined acceptable difference before retiring the old lot. A typical procedure looks like this:
- Identify the trigger. A new lot number, a new shipment of an already-qualified lot (if your procedure requires shipment-level verification), or a reagent that has had any formulation or manufacturing change flagged by the manufacturer.
- Select verification material. Most laboratories use commercial QC material at two or three levels spanning the reportable range (including levels near clinically meaningful decision points), and/or a small panel of patient specimens spanning low, mid, and high analyte concentrations. Check your assay’s own package insert and your laboratory’s SOP — some manufacturers specify a minimum number of levels or replicates.
- Run the new lot and the current lot in parallel on the same material, in the same run where practical, using the same operator and instrument to remove those as variables.
- Compare results against a predefined acceptance criterion — commonly expressed as a maximum allowable difference, a percentage deviation, or agreement within the assay’s established total allowable error, set in advance in the SOP rather than judged after the fact.
- Document the comparison on a new reagent lot verification form: both lot numbers, the material used, the individual results from each lot, the calculated difference, the acceptance criterion, the reviewer’s sign-off, and the date the new lot was released to clinical use.
- Resolve and repeat if the new lot fails the acceptance criterion — investigate (instrument, calibration, control material expiration) before assuming the new reagent lot itself is at fault, and do not release the new lot for patient testing until the discrepancy is explained and a passing verification is documented.
- Retain records per your laboratory’s document retention policy and the retention period your accrediting body requires for QC records generally.
What belongs on a new reagent lot verification form
A lot verification form doesn’t need to be complicated, but CAP and CLIA inspectors will look for specific elements when they ask to see it. At minimum, include:
- Test/assay name and instrument or method
- Outgoing (current) lot number and expiration date
- Incoming (new) lot number and expiration date
- Verification material used (control level(s) and/or patient specimen identifiers, de-identified per your policy)
- Results for each material on both lots, side by side
- The predefined acceptance criterion, stated explicitly, not just “pass/fail”
- Calculated difference or percent deviation for each comparison point
- Reviewer name/initials and date of review
- Date the new lot was approved for clinical use
- Space to document any failed comparison, the investigation, and corrective action
Many laboratory information systems (LIS) and quality management platforms include a built-in reagent lot verification module that auto-populates the outgoing lot’s historical data, which reduces transcription error compared with a standalone paper or spreadsheet form — but the elements above are what an inspector is checking for regardless of which format the record takes.
Qualitative and semi-quantitative assays
Not every test produces a continuous numeric result that supports a percent-deviation calculation. For qualitative assays (many antigen and antibody tests, blood bank reagents, rapid tests), lot-to-lot verification typically means confirming that the new lot correctly identifies known positive and known negative material, and that any semi-quantitative grading (e.g., reaction strength) is consistent with the outgoing lot, rather than calculating a numeric difference. The acceptance criterion in these cases is usually “correct classification of all known-result material,” documented the same way as a quantitative comparison.
Common pitfalls in reagent lot-to-lot verification
Laboratories tackling reagent lot-to-lot verification in day-to-day operation run into a fairly consistent set of problems:
- No predefined acceptance criterion. Comparing two lots and deciding afterward whether the difference “looks fine” is not a verification procedure an inspector will accept, and it invites inconsistent decisions between staff members.
- Verifying against expired or out-of-range control material, which can make an acceptable new lot look like it failed, or worse, mask a real problem with the new lot.
- Skipping verification for “the same reagent, just restocked” when the shipment actually carries a new lot number — the lot number on the box, not the product name, is what should trigger the procedure.
- Treating verification as a one-time check at implementation rather than a documented step every time the lot changes, including for reagents used infrequently.
- Missing the sign-off/review step. A completed comparison sitting in a binder without a reviewer’s documented approval is a common inspection finding even when the underlying data would have passed.
- Not linking the verification record to the lot number in the LIS or instrument log, which breaks the traceability the whole process exists to establish if a result is ever questioned later.
Frequently asked questions
What is a reagent lot?
A reagent lot is a batch of reagent manufactured together under the same conditions and identified by a single lot (batch) number. All units carrying that number are presumed to share the same performance characteristics because they came from the same manufacturing run.
What is reagent lot-to-lot verification?
It’s the documented process of comparing a new reagent lot against the current lot — usually by running both on the same QC material or patient specimens — to confirm the new lot performs within an acceptable, predefined range of the old lot before it is used for patient testing.
Does CAP require a specific reagent lot number verification form?
CAP doesn’t mandate a specific form template, but its checklist requirements (commonly referenced under an item such as COM.30450 in current General/Common checklist editions — confirm the exact number against your active checklist) expect a documented procedure and retained records showing what was compared, the acceptance criterion, the outcome, and reviewer sign-off. Any form or LIS module that captures those elements satisfies the intent.
Is lot-to-lot verification required for CLIA-waived tests?
CLIA’s nonwaived-testing control-procedure regulations don’t apply to waived tests, but manufacturers frequently instruct operators, in the package insert, to run controls with each new lot or shipment — and CLIA requires waived testing to follow the manufacturer’s instructions, which in practice still requires a lightweight lot check at many waived sites.
Do I need to verify every new shipment, or only every new lot number?
At minimum, every new lot number needs verification. Many laboratory SOPs also require verification of new shipments of an already-verified lot, since shipping and storage conditions (temperature excursions in transit, for example) can affect reagent performance independently of the manufacturing lot itself — check your own SOP and, where applicable, your accrediting body’s current checklist language for which trigger it specifies.
Related CASRAI resources
See also Certificate of Analysis (COA) for how manufacturer-provided lot documentation fits into incoming reagent QC, Chemical Grades Explained for what “reagent grade” itself means, Temperature Excursion for handling a shipment where storage conditions may have been compromised, and Vendor Qualification Process for the broader supplier-qualification framework this procedure sits within.
